Article info

Download PDFPDF

Original research
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

Authors

  1. Correspondence to Dr Matthew Baker; mbake13{at}stanford.edu
View Full Text

Citation

Baker M, Chaichian Y, Genovese M, et al
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

Publication history

  • Received October 17, 2020
  • Revision received December 12, 2020
  • Accepted December 17, 2020
  • First published December 30, 2020.
Online issue publication 
December 30, 2020
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.